贝利尤单抗在肾移植中的应用:一项实验医学、随机、安慰剂对照2期试验
这项双盲、随机、安慰剂对照2期试验在两家中心纳入28例成人肾移植受者,1:1随机接受静脉贝利尤单抗10 mg/kg或安慰剂(第0、14、28天,之后每4周,共7次输注),联合标准免疫抑制(巴利昔单抗、吗替麦考酚酯、他克莫司和泼尼松龙)。主要终点为安全性和第24周初始B细胞浓度较基线的变化。贝利尤单抗组与安慰剂组不良事件比例相似,严重感染在治疗期分别为1/12(8%)和5/13(38%)。第24周初始B细胞减少未达主要终点(校正均值差-34.4个细胞/μL,95%CI -109.5至40.7)。作者认为贝利尤单抗可能是有用的辅助治疗,无重大感染风险增加,且可能对体液同种免疫有益。
要点
- 贝利尤单抗10 mg/kg静脉输注(第0、14、28天,之后每4周,共7次)联合标准免疫抑制,未显著减少第24周初始B细胞(校正均值差-34.4个细胞/μL,95%CI -109.5至40.7)。
- 严重感染在6个月治疗期贝利尤单抗组1/12(8%) vs 安慰剂组5/13(38%),随访期分别为0和2/13(15%)。
- 治疗期安慰剂组1例死于致命性心肌梗死和急性心力衰竭。
- 作者认为贝利尤单抗可能是有用的辅助治疗,无重大感染风险增加,且可能对体液同种免疫有益。
适用人群与场景
- 年龄18-75岁、接受肾移植并计划接受标准免疫抑制(巴利昔单抗、吗替麦考酚酯、他克莫司和泼尼松龙)的成人受者。
处置流程与药物剂量
- 贝利尤单抗10 mg/kg体重静脉给药,第0、14、28天,之后每4周,共7次输注,联合标准免疫抑制(巴利昔单抗、吗替麦考酚酯、他克莫司和泼尼松龙)。
研究设计与关键结果
- 双盲、随机、安慰剂对照2期试验,在Addenbrooke's Hospital(剑桥)和Guy's and St Thomas' Hospital(伦敦)两家中心进行;303例评估资格,28例随机(贝利尤单抗n=14,安慰剂n=14),25例接受移植并至少一剂药物纳入mITT(贝利尤单抗12例[86%],安慰剂13例[93%])。
- 主要终点之一第24周初始B细胞减少未达到:贝利尤单抗组与安慰剂组校正均值差-34.4个细胞/μL(95%CI -109.5至40.7)。
- 不良事件比例两组相似;严重感染在6个月治疗期贝利尤单抗组1/12(8%) vs 安慰剂组5/13(38%),6个月随访期贝利尤单抗组0 vs 安慰剂组2/13(15%)。
- 治疗期安慰剂组1例死于致命性心肌梗死和急性心力衰竭。
证据类型、等级与局限
- 证据类型:随机、双盲、安慰剂对照2期试验;原文未报告证据等级。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为贝利尤单抗可能是有用的辅助治疗,无重大感染风险增加,且可能对体液同种免疫有益。
指南或共识出处
- ClinicalTrials.gov注册号NCT01536379;EudraCT注册号2011-006215-56。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: B cells produce alloantibodies and activate alloreactive T cells, negatively affecting kidney transplant survival. By contrast, regulatory B cells are associated with transplant tolerance. Immunotherapies are needed that inhibit B-cell effector function, including antibody secretion, while sparing regulators and minimising infection risk. B lymphocyte stimulator (BLyS) is a cytokine that promotes B-cell activation and has not previously been targeted in kidney transplant recipients. We aimed to determine the safety and activity of an anti-BLyS antibody, belimumab, in addition to standard-of-care immunosuppression in adult kidney transplant recipients. We used an experimental medicine study design with multiple secondary and exploratory endpoints to gain further insight into the effect of belimumab on the generation of de-novo IgG and on the regulatory B-cell compartment.
METHODS: We undertook a double-blind, randomised, placebo-controlled phase 2 trial of belimumab, in addition to standard-of-care immunosuppression (basiliximab, mycophenolate mofetil, tacrolimus, and prednisolone) at two centres, Addenbrooke's Hospital, Cambridge, UK, and Guy's and St Thomas' Hospital, London, UK. Participants were eligible if they were aged 18-75 years and receiving a kidney transplant and were planned to receive standard-of-care immunosuppression. Participants were randomly assigned (1:1) to receive either intravenous belimumab 10 mg per kg bodyweight or placebo, given at day 0, 14, and 28, and then every 4 weeks for a total of seven infusions. The co-primary endpoints were safety and change in the concentration of naive B cells from baseline to week 24, both of which were analysed in all patients who received a transplant and at least one dose of drug or placebo (the modified intention-to-treat [mITT] population). This trial has been completed and is registered with ClinicalTrials.gov, NCT01536379, and EudraCT, 2011-006215-56.
FINDINGS: Between Sept 13, 2013, and Feb 8, 2015, of 303 patients assessed for eligibility, 28 kidney transplant recipients were randomly assigned to receive belimumab (n=14) or placebo (n=14). 25 patients (12 [86%] patients assigned to the belimumab group and 13 [93%] patients assigned to the placebo group) received a transplant and were included in the mITT population. We observed similar proportions of adverse events in the belimumab and placebo groups, including serious infections (one [8%] of 12 in the belimumab group and five [38%] of 13 in the placebo group during the 6-month on-treatment phase; and none in the belimumab group and two [15%] in the placebo group during the 6-month follow-up). In the on-treatment phase, one patient in the placebo group died because of fatal myocardial infarction and acute cardiac failure. The co-primary endpoint of a reduction in naive B cells from baseline to week 24 was not met. Treatment with belimumab did not significantly reduce the number of naive B cells from baseline to week 24 (adjusted mean difference between the belimumab and placebo treatment groups -34·4 cells per μL, 95% CI -109·5 to 40·7).
INTERPRETATION: Belimumab might be a useful adjunct to standard-of-care immunosuppression in renal transplantation, with no major increased risk of infection and potential beneficial effects on humoral alloimmunity.
FUNDING: GlaxoSmithKline.
参考来源
- Banham GD, Flint SM, Torpey N, et al. Belimumab in kidney transplantation: an experimental medicine, randomised, placebo-controlled phase 2 trial. Lancet. 2018. PMID: 29910042. doi:10.1016/S0140-6736(18)30984-X
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。